# BOOST-RCC (NCT06284564)

> A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

No report yet. It can be ordered.

- Drugs tested: evolocumab plus nivolumab
- Indication: metastatic renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06284564
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Metastatic Renal Cell Carcinoma
- Interventions: Evolocumab; Nivolumab
- Enrollment: 10
- Primary outcome: Safety and adverse events (AEs)

## Indexed commentary on BOOST-RCC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 5
- X threads: 4
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=boost-rcc-nct06284564

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06284564", "email": "<work email>"}; the inbox owner confirms by the emailed link.